Pacira BioSciences, Inc.
$ 24.72
3.60%
17 Apr - close price
- Market Cap 1,063,486,000 USD
- Current Price $ 24.72
- High / Low $ 24.89 / 23.81
- Stock P/E 154.50
- Book Value 16.86
- EPS 0.16
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.01 %
- 52 Week High 27.64
- 52 Week Low 18.80
About
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.
Analyst Target Price
$28.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-08-05 | 2025-05-05 | 2025-02-26 | 2024-11-06 | 2024-07-30 | 2024-05-07 | 2024-02-29 | 2023-11-02 | 2023-08-02 | 2023-05-03 |
| Reported EPS | 0.57 | 0.7 | -0.11 | 0.62 | 0.91 | 0.79 | 0.89 | 0.62 | 0.89 | 0.72 | 0.78 | 0.53 |
| Estimated EPS | 0.9017 | 0.65 | 0.72 | 0.5971 | 0.8303 | 0.7 | 0.7 | 0.62 | 0.88 | 0.78 | 0.76 | 0.62 |
| Surprise | -0.3317 | 0.05 | -0.83 | 0.0229 | 0.0797 | 0.09 | 0.19 | 0 | 0.01 | -0.06 | 0.02 | -0.09 |
| Surprise Percentage | -36.7861% | 7.6923% | -115.2778% | 3.8352% | 9.5989% | 12.8571% | 27.1429% | 0% | 1.1364% | -7.6923% | 2.6316% | -14.5161% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCRX
2026-04-17 09:09:10
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced it will report its first quarter 2026 financial results after the market close on Thursday, April 30, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss the results. Interested parties can pre-register for the call or access a live audio webcast on Pacira's investor relations website.
2026-04-16 12:10:20
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced it will report its first-quarter 2026 financial results after the U.S. markets close on Thursday, April 30, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET, with a replay available on their website for approximately two weeks. Pacira is an industry leader in non-opioid pain therapies, with several commercial-stage treatments and a developing pipeline.
2026-04-16 12:10:20
Pacira BioSciences (Nasdaq: PCRX) announced it will report its first-quarter 2026 financial results after market close on Thursday, April 30, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET following the release, with registration required for telephone participants to receive dial-in information and a PIN. A webcast replay will be available on Pacira's website for approximately two weeks.
2026-04-16 11:39:31
Pacira BioSciences, Inc. announced that it will report its first-quarter 2026 financial results after U.S. markets close on Thursday, April 30, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET following the release, accessible via pre-registration for telephone participants or through the "Events" page on its investor relations website.
2026-04-14 20:10:20
Pacira BioSciences (NASDAQ:PCRX) has received an average "Hold" rating from analysts, with a 12-month average price target of $30.25. Recent insider sales include Jonathan Slonin and Lauren Riker reducing their stakes. The company missed its latest quarterly earnings and revenue estimates, reporting EPS of $0.57 against a consensus of $0.85 and revenue of $196.87M against $201.93M.
2026-04-13 20:10:20
Pacira BioSciences, Inc. presented real-world data at the AMCP 2026 Meeting demonstrating that its non-opioid pain therapy, EXPAREL, is associated with lower total healthcare costs and reduced opioid use in outpatient total hip and knee arthroplasty procedures. The studies showed cost savings over various follow-up periods, particularly for patients with lower back pain and in teaching hospitals. The findings reinforce EXPAREL's economic value and role in advancing non-opioid pain management solutions for patients, providers, and payers.
